Our mission is to help those people end their chronic joint pain and get back

to an active lifestyle by connecting them with the Regenokine® Program.

Take a Deeper Dive

Learn more about the Regenokine Program

For more than 20 years, Dr. Peter Wehling and his team1 have conducted intensive research that has advanced the understanding and treatment options in orthopedics, musculoskeletal pain conditions and aging. Members[1] of the team are recognized international experts and have shaped the field of regenerative pain medicine and the development of innovative pain therapies. Their findings have resulted in the development and implementation of the personalized Regenokine® Program – treating the underlying biomolecular disease processes and not merely their symptoms. The Regenokine® Program has allowed most patients to pursue everyday activities free of complaints and has prolonged the active career of many professional athletes.

Dr. Wehling and this team’s vision-and-mission:

  • To alter the process of aging and thereby empowering people to restore their youthful biology and enhancing the way they live.


Regardless of age, modern society often envisions an independent future with the best quality of life possible free of pain. Critical to independence is the ability to function and exercise without pain. Preserving the health of our joints is critical for maintaining independence and freedom at any age.

[1] Members: Prof. Dr. med. Peter Wehling; Dr. med. Jana Wehling; Dr. rer. nat. Julio Reinecke; Glyn Hamed; Chris Evans, PhD; Laura Timmerman, MD; Chris Renna, DO; Thomas Buchheit, MD; William Maixner, DDS, PhD (in memoriam)

Aging is complex and multifaceted, affected by an interaction of environmental, genetic and epigenetic factors. Major causes and accelerators of aging are DNA damage, oxidative stress, regenerative deficiency and chronic low-grade inflammation. These processes are universally present, independent of disease and tissue (e.g., orthopedic, dermatologic, neurologic and cardiovascular diseases). Musculoskeletal aging is particularly apparent in movement and its restrictions; the speed and smoothness of a person’s movement can be used to draw conclusions about their age and state of health. Thus, healthy joints have a positive impact on our self-perception of resilience and project the perception of youth and health.

The identification and validation of causal therapies targeting fundamental mechanisms is a critical unmet need and form the basis of molecular orthopedics – a science dedicated to decoding cellular language and underlying biological mechanisms. Molecular orthopedics is paving the way to new treatment approaches that restore joint health and not merely suppress symptoms.

The Regenokine® Program has demonstrated success in the treatment of world-class athletes, leisure sports enthusiasts, and those who wish to maintain a highly functional lifestyle following acute injuries or who suffer from chronic pain. The Program is designed to help patients of any age to restore or maintain vitality and quality of life – free of pain.

Dr. Wehling and his international research team, has developed and implemented into clinical practice a new treatment program – the Regenokine® Program that targets destructive and pain producing mechanisms found in diseased tissue. The Program uses established unique procedures and adjuvant treatments with the goal to restore healthy conditions by engaging the total potential of the immune system.

In this section of the side, several important questions are addressed: 

  1. What are the causes of pain, aging and orthopedic diseases? Can there be a non-mechanical explanation placing biomolecular changes like inflammation at the heart of the problem?
  2. Why and how can current treatment options be limited?
  3. How can we engage the body‘s innate immune system and effective mediators?
  4. What are the ideal components for a clinical program to manage tissue destruction, pain and functional impairment?
  5. How can we relieve patient suffering? How can we better understand patients‘ needs and provide them with the best treatment?

With innovative scientific insights, the Regenokine® Program was launched to address these questions and is continuously being honed over to maximize its clinical effectiveness. Treatment options associated with the Program are custom-tailored to meet the needs of each individual patient. The Program has integrated state-of-the-art diagnostics, unique treatment methods and lifestyle measures.

The central module is the Regenokine® Program, injection therapies with autologous (body-own) mediators.

The Regenokine® Program amongst others engages the patients‘ own capabilities of the immune system and utilizes a multitude of autologous mediators, such as growth factors and cytokines, as therapeutic effector molecules.

Growth factors, for example, have been ascribed with potent anti-inflammatory and regenerative effects, directly intervening in underlying biological mechanisms not merely of pain but also of pathology itself (1). Through this, the Regenokine® Program pursues a comprehensive, targeted and physiological approach with the goal to restore natural balance and healthy conditions in diseased tissue.

A critical lack of effective and safe orthopedic treatments exists (2). The Regenokine® Program, seeks to narrow the gap of this unmet medical need.

Prof. Peter Wehling in the 1990s starting his work in regenerative medicine

Osteoarthritis (1)

Osteoarthritis is an undervalued health crisis.

Osteoarthritis is a chronic disease that is increasing in occurrence and seriously impacts our society. Osteoarthritis affects approximately 10% of men and 18% of women over the age of 60. Serious individual consequences regarding health and finances, as well as a major socioeconomic and financial burden of over $486 billion are attributed to osteoarthritis in the US (2, 3).

Osteoarthritis is a complex multifactorial disease characterized by biomolecular changes such as chronic inflammation. The main risk factor for osteoarthritis and tissue degeneration is age. Besides genetic factors, the inflammatory status, immune system activity and a preponderance of destructive mediators count as biologic risk factors. Acute as well as chronic mechanical stress (e.g. injury, sports, overweight, surgery, skeletal deformities) are factors associated with premature wear and tear.


• Age (main risk factor)
• Inflammation
• Obesity
• Genetic predisposition
• Excessive physical strain in certain sports
• Prior joint injuries
• Prior surgery
• Anatomic abnormalities (instability,


• Pain at initiation of movement
• Pain through load or weight-bearing
• Pain at rest and at night with disease
• Restricted mobility and stiffness
• Excessive fluid within the joint and thus, swelling of the joint

Osteoarthritis (2)

Main signs and symptoms of osteoarthritis are structural changes like cartilage loss, inflammation, oxidative stress, pain and reduced mobility. These changes may not merely have impact on daily functioning but also on our emotional well-being. Symptoms as well as disease progression vary greatly between individuals, however, often as the disease progresses, pain becomes constant, even at rest. Joint swelling and warmth may indicate an activated osteoarthritis linked to a higher inflammatory level (4).

Patients often treat worsening of pain with rest. However, a lack of exercise may speed up destructive processes and worsen the condition. Simultaneously, ligaments and muscles supporting the joint diminish and weaken. Muscular insufficiencies and structural changes can aggravate symptoms.

Rest is not the answer; the right type of activation and strengthening however is.


  • In principle, any joint can be affected, yet the knee, hip and spine are particularly susceptible
  • A biological imbalance in favor of inflammation and damaging proteins plays an important role in driving pain as well as disease development and progression
  • Osteoarthritis is not only associated with cartilage defects, but with changes of the entire joint and surrounding tissue (joint capsule, bone, ligaments and muscles)

images provided by Dr. Philip May (Düsseldorf)

Progression of Osteoarthritis (according to Kellgren-Lawrence scale I-IV)

It is important to note that pain and symptoms do not always correspond to the radiological stage of osteoarthritis. The gap between image and pain report further emphasizes the importance of biological processes impacting pain.

We treat the patient and not the radiological image.

Sports Injuries & Cartilage Defects

Competitive athletes and weekend warriors train their bodies to the full extent of possibilities to be able to retrieve their strongest performances when needed. Level and quality of performance directly correlate with physical abilities of the body, making the absence of injury and disease crucial.

However, the body and the components of the joint are not without their limits. Extensive overuse and microtrauma are factors related to regular practice and matches. High levels of mechanical stress paired with limited resting episodes can be common risk factors for development and progression of cartilage defects, swollen and inflammatory joints, tissue damages and commencing signs of osteoarthritis.


  • The knee, hip and shoulder are particularly susceptible for sports related injuries but in principal, any joint can be affected.
  • Cartilage defects are the second most common injury in the NBA and the injury associated with the most games missed (20)
  • A biological imbalance in favor of inflammation and damaging proteins plays also an important role in driving pain as well as disease development and progression in sports related injuries and cartilage defects.

Cartilage defects as well as osteoarthritis are complex multifactorial conditions associated with biomolecular changes. Besides genetic factors, the inflammatory status, immune system activity and a preponderance of destructive mediators count as biologic risk factors. Due to the extensive level of activity accompanying professional sports and regular recreational sports, constant mechanical stress exerted onto joints may result in progression of disease.

Cartilage defects can progress into posttraumatic osteoarthritis.

These MRIs show a cartilage defect behind the knee cap from two different perspectives. Cartilage defects usually result from mechanical trauma, however the cellular response to the trauma determines the further course of disease and pain level. Excessive fluid is a sign of an inflammatory environment inside the joint.

Comprehending not only the mechanical properties of sports-related injuries but also the biological properties is paramount to providing the best conditions to treat injuries, recover full function, and avoid progression to more severe or chronic diseases (5).

Molecular Orthopedics

Molecular orthopedics seeks to understand the biological causes of musculoskeletal disorders and to facilitate targeted, disease-altering treatments. This field utilizes the strengths of orthopedic surgery, molecular biology, and physiology to decode the complexities of diseases such as osteoarthritis.

”There is no creation without destruction.“ Joints of healthy individuals maintain a natural balance between destructive and protective processes mediated by various proteins. This balance is vital for health and fluent joint movement.  People with osteoarthritis, however, usually have a preponderance of destructive and pro-inflammatory proteins that may cause disease progression, impair normal joint function and produce pain. Cells in a balanced joint are programmed to produce proteins that promote health and regeneration.

The Regenokine® Program aims to re-establish this critical balance for tissue health. Biomolecular insights gained through years of research of Dr. Wehling and his team, makes striving for the restoration of tissue health.

Universal biological changes over the short- or long-term driving pain, disease development and progression include, but are not limited to: (6, 7, 8)

  • Chronic low-grade inflammation
    • Oxidative stress
    • Expression of destructive enzymes • Regenerative deficiency
    • Cellular aging

It is not a sole mechanical wear and tear; rather a progressive degrading of tissue cells, such as cartilage, that is driven by intrinsic biomolecular processes leading to pain and progressive

tissue damage. Mechanical means may act as a trigger or amplifier, yet the acting causes are on molecular and genetic level – as molecular orthopedics demonstrates.

The goals of molecular orthopedics, regenerative medicine, and the Regenokine® Program are unified in targeting not just the symptoms, but the underlying biomolecular causes for development and progression of pain, on the one hand and osteoarthritis, cartilage defects and soft tissue injuries on the other.

The spectrum of currently available treatment options in osteoarthritis and cartilage defects has major drawbacks in terms of safety and efficacy. Current treatments are largely palliative, designed to improve symptoms or to address mechanical matters until surgical interventions appear unavoidable. Conventional treatments don’t address fundamental biological mechanisms of disease development and progression, neither address those who are relevant for restoration of healthy condition.

Commonly used analgesic medication such as acetaminophen, NSAIDs (non-steroidal anti- inflammatory drugs) and opioids represent effective alternatives for acute and short-term pain management. However, in the long term they are associated with little improvement and their risks, including cardiovascular diseases, gastric bleeding, hospitalization, persistent disability or premature death, often outweigh advantages. Overuse can lead to severe consequences individually as well as socioeconomically, with the epidemic opioid crisis being an appalling example.

Intra-articular steroid injections provide a rapid but short-term pain relief (1-6 weeks) and are commonly used for disease with inflammatory components.

In the short-term, they can have a beneficial and protective role on cartilage cells. However, repeated and long-term use, as it is often necessary in the treatment of a chronic disease with little to no long-term alternatives, may potentially damage articular tissue (2).

For a critical overview and evaluation of alternative treatments available we refer to the most current guidelines of the Osteoarthritis and Research Society International (OARSI) and American Academy of Orthopedic Surgeons (AAOS ) (9, 21).

Surgery has historically been seen as the remedy for osteoarthritis when non-operative treatment alternatives have failed. Yet, concerns regarding increasing surgical interventions have arised, partially due to a lack of high-quality scientific studies. Thoughtful and patient-orientated surgical decision-making should be part of the pursuit for safe and effective treatments. Even if surgery manage to repair the mechanical setting (joint congruency, alignment, etc.) biological aspects must be treated for achieving true restoration of a healthy joint.

The Regenokine® Program opens a new non-surgical and sustainable treatment option that targets the underlying mechanisms not merely relevant to pain but also ones directly relevant to the disease itself.

The Regenokine® Program is a holistic, sustainable and customized treatment system consisting of multiple elements.

The Regenokine® Program incorporates best in-practice diagnostics, unique therapies and lifestyle measures tailored to the needs of each patient. The core element of the Program is a distinctive injection therapy derived from one’s own blood – the Regenokine® Procedure. In addition to a medical treatment, the customization incorporates rehabilitative and preventive options such as physiotherapy, nutrition, lifestyle measures and exercise. The treatment goals of the Regenokine® Program are to restore physiological tissue health, diminish pain, improve function, inhibit disease progression; collectively resulting in an improvement in life quality while at the same time

reducing the need for surgery. For athletes, this may come with an extension of career and a greater player value.

Further information is outlined in the book “The End of Pain“ by Peter Wehling and Chris Renna: https://amzn.to/2Nqi0pA.

Components of the diagnostic procedures include, but are not limited to:

• Clinical examination
• Standardized documentation with validated
questionnaires and scores
• Radiological imaging
• Blood tests (including laboratory chemical
parameters, inflammatory markers, genetic
susceptibility analysis and screening for
autoimmune diseases, etc.)

Autologous Serum




Regenerative sleep



Weight reduction
(in case of obestity)


Social support

Psychological support

Anti-inflammatory &
anti-oxidative nutrition

The Regenokine® Program is customized toward the needs of each patient. The Program utilizes a novel and patented injection treatment that is paired with additional treatment procedures, such as physiotherapy, osteopathy, nutrition and other anti inflammatory and regenerative approaches to achieve durable improvement.

Osteoarthritis and cartilage defects are currently the most commonly treated diseases based on the Research teams clinical experience, although the Regenokine® Program is also used to treat acute and chronic spine diseases as well as soft tissue injuries (such as injuries/conditions in muscles, tendons, ligaments or exemplary in meniscus). In certain cases, the Regenokine® Program

has been applied outside of the orthopedic field in diseases involving inflammatory processes to achieve pain reduction, symptom reduction or to inhibit tissue destruction.

Based on long-term clinical expertise and randomized clinical trials, the Regenokine® Program can be a treatment option in the following conditions:


Cartilage defects
Meniscus Tears


Rotator cuff injuries


Disc prolapse
Nerve root irritation
Facet osteoarthritis
Spinal canal stenosis


Any joints of fingers
and hands afflicted
with osteoarthritis


Labrum tear


Tendon injury


Various types of
muscles tears
and inflammatory


Golfer‘s or Tennis

*painful syndrom of the achilles tendon

Images provided by Dr. Philip May (Düsseldorf)

These images of a knee from the side compare the radiological findings in a patient with meniscus tear before and after undergoing the Regenokine® Program. The outcome may be due to the Regenokine® Program, the natural course of the disease itself or a combination of the two. Yet, these observations match with the findings of study by Strümper, where 83% of patients with meniscus tears could avoid surgery with the application of autologous serum alone (15).

Spectrum of Treatment Options (1)

The major orthopedic societies (OARSI, ACR, AAOS, etc.) concur that currently approved standard of care treatments in osteoarthritis and ones in pipeline seriously lack efficacy and/ or safety creating major unmet medical needs. Non-surgical interventions for Osteoarthritis and cartilage defects overlap and share similar principles.

To put our injection therapies into perspective, depicted on the next page are therapeutic efficacy, number-needed-to-treat and side- effect profiles of frequently used alternatives in comparison to our treatments. Recommendations for use by grand orthopedic societies are controversial and point out the major lack of efficacy and/or safety. Studies were chosen on the basis of the following selection criteria: availability of raw data, randomized and con- trolled study design, consistency of manuscript, sample size (see following table on p.15).

Spectrum of Treatment Options (2)

The following table shows intra-articular and oral treatment options in painful osteoarthritis.

In statistics, an effect size (ES) is a number measuring the strength of a treatment over a comparison. The higher the effect size, the better the success of a treatment. This has been measured in various studies in pain as well as in function.

The number needed to treat (NNT) displays how many patients need to be treated for one patient to benefit from a certain treatment. The lower the NNT, the higher the efficacy.

In a randomized trial with 376 patients by Baltzer et al., autologous serum treatment demonstrated a high effect on pain and function, paired with a low side-effect profile.

1-5 according references where data is derived from can be found in the Reference section

Data evaluated in knee OA at 6 months where possible vs control:

Autologous Serum: 26w vs PL
GC bottom row: 26w vs PL2
HA: 12w vs PL2

PRP: 24w vs HA3,4 vs GC5
Stem Cell: 24w vs HA6;
12mo vs GC7
NSAIDs: 12w vs PL2
Acetaminophen: 26w vs PL2
Opioids: 12w vs PL2

Frequently Asked Questions

The Regenokine® Program has been in clinical use for approximately 10 years. It is estimated that over 20 000 patients have been treated with the Regenokine® Program in Europe and the US in this time period. Over 100 000 patients have been treated with sole serum injections.
Depending on the treated disease, the Regenokine® Program is performed either as a one-day treatment, or a 4-5 day program. Factors influencing this decision include type and severity of a disease, clinical complaints and comorbidities (pre-existing illnesses).
Duration of effect depends on the individual, the treated disease and its severity. We typically note a lasting effect between 1 to 5 years in knee and hip osteoarthritis. In disc prolapses we sometimes observe a permanent effect, this may be due to the Regenokine® Program, the natural course of the disease itself or a combination of the two.

Individual responder rate depends on the type of disease, severity, individual pain situation and other factors.

We estimate that approximately 75% in patients with mid-stage knee osteoarthritis and an “average pain profile” will experience success with the treatment. This conversely means that a small percentage of patients notice only a small change or no change at all.

We define treatment success when a patient achieves an improvement by 50% or greater. This improvement can refer to pain reduction or improved function (daily activities or sports). We use standardized questionnaires and scores to compare clinical parameters before and after treatment.

The treatment can be repeated if the patient responds well. An interval of 2 two 4 years tends to be the average of frequency in osteoarthritis.

Overall, downtime is significantly shorter compared to surgery. Typically, downtime for competitive athletes can range from 1-2 weeks – depending the individual case this may differ. Patients that aren’t exposed to an extensive physical load, usually have no downtime at all.

We take care of patients of any age (18-99 years) and profession. The Program has been used successfully in the treatment of popes, princes, professional athletes and film and music stars, as well as thousands of less famous people. Amongst the 20 000 patients, we have treated world class NBA players, top ten ATP tennis players, former PGA champions, UFC champions, the world’s finest ballet dancers, NHL players, soccer players, professional skiers and players from the national Olympic teams (including the US Team).

With the utmost discretion, we have the honor that players of the following sports teams have entrusted us with their health.



• Atlanta Hawks
• Brooklyn Nets
• Denver Nuggets
• Golden State Warriors
• Houston Rockets
• Memphis Grizzlies
• Miami Heat
• Minnesota Timberwolves
• New Orleans Hornets
• NY Knicks
• Orlando Magic
• Oklahoma City Thunder
• Philadelphia 76er
• Phoenix Suns
• Portland Trail Blazers
• Washington Wizards

American Football:

• Arizona Cardinals
• Atlanta Falcons
• Buffalo Bills
• Chicago Bears
• Dallas Cowboys
• Denver Broncos
• New England Patriots
• New Orleans Saints
• New York Jets
• Oakland Raiders
• Pittsburgh Steelers
• San Diego Chargers
• Tampa Bay Buccaneers


• Colorado Rockies
• Florida Marlins
• Houston Astros
• NY Yankees
• Philadelphia Phillies

European Soccer:

• FC Chelsea
• FC Bayern München
• Borussia Dortmund
• FC Schalke 04
• FC Leipzig
• Bayer 04 Leverkusen
• Borussia Mönchengladbach
• AS Monaco

We want to emphasize that the Regenokine® Program can be a treatment alternative independent of age and profession.

Definitions & Abbreviations

Autologous Serum:
Autologous conditioned serum describes the composition of body-own serum with biological and clinical effects. Autologous Serum is cell-free and defined as the physiological whole blood secretome containing the totality of mediators released from blood cells.

Regenokine® Program:
The Program describes an individualized multimodal treatment program for orthopedic diseases and pain conditions. It is built from unique elements of diagnostics, therapeutics and lifestyle measures with the central module being the autologous serum.

FGF: Fibroblast growth factor

HGF: Hepatocyte growth factor

IGF: Insulin-like growth factor

IL-1: Interleukin-1 (pro-inflammatory cytokine)

IL-1Ra: I Interleukin-1 Receptor-antagonist

KLS: Kellgren-Lawrence-Scale

NSAID: Non-steroidal anti-inflammatory drug

PRP: Platelet-rich plasma

TGF: Transforming growth factor beta



  1. Lidder S, Chubinskay S. Post-Traumatic Osteoarthritis: Biologic Approaches to Treatment. in: Principles of Osteoarthritis – Its Definition, Character, Derivation and Modality-Related Recognition. InTech; 2012. p. 1–29.
  2. Osteoarthritis Research Society International. Osteoarthritis: A Serious Disease. Osteoarthritis Research Society International; 2016. pp. 1–103 (White Paper)
  1. Source: Medical Expenditures Panel Survey (MEPS), Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, 2008-2014, Table 8.13
  2. Brandt, KD. Diagnosis and Nonsurgical Management of Osteoarthritis (Vol. Fifth Edition). p15-88, p265-270. Professional Communications, Inc. 2010.
  3. Borrelli J, Olson S, Godbout C., Schemitsch E., Stannard J., Giannoudis P. (2019). Understanding Articular Cartilage Injury and Potential Treatments. Journal of orthopaedic trauma. 33 Suppl 6. S6-S12. 10.1097/BOT.0000000000001472.
  4. Chen, D., Shen, J., Zhao, W. et al. Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Res 5, 16044; 2017. https://doi.org/10.1038/boneres.2016.44
  5. Chow YY, Chin, K-Y. The Role of Inflammation in the Pathogenesis of Osteoarthritis. Mediators Inflamm. 2020; 2020: 8293921. Published online 2020 Mar 3. doi: 10.1155/2020/8293921. PMID: 32189997
  6. Lepetsos P, Papavassiliou AG. ROS/oxidative stress signaling in osteoarthritis. Biochim Biophys Acta – Mol Basis Dis. Elsevier B.V.; 2016 Apr;1862(4):576–591. PMID: 26769361
  7. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, Blanco FJ, Espinosa R, Haugen IK, Lin J, Mandl LA, Moilanen E, Nakamura N, Snyder-Mackler L, Trojian T, Underwood M, McAlindon TE. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. Elsevier Ltd; 2019;27(11):1578–1589. PMID: 31278997. Supplementary Material „Evidence Report: OARSI Treatment Guidelines for the Non-Surgical Management of Osteoarthritis“ 09/2018.
  8. Tohidnezhad M, Bayer A, Rasuo B, Hock JVP, Kweider N, Fragoulis A, Sönmez TT, Jahr H, Pufe T, Lippross S. Platelet- Released Growth Factors Modulate the Secretion of Cytokines in Synoviocytes under Inflammatory Joint Disease. Mediators Inflamm. 2017;2017:1046438. doi: 10.1155/2017/1046438. Epub 2017 Nov 19. PMID: 29348703; PMCID: PMC5733972
  9. Circolo A, Pierce GF, Katz Y, Strunk RC. Antiinflammatory effects of polypeptide growth factors. Platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor inhibit the cytokine-induced expression of the alternative complement pathway activator factor B in human fibroblasts. J Biol Chem. 1990 Mar 25;265(9):5066-71. PMID: 1690734.
  10. Wojdasiewicz P, PoniatowskiŁ A, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014;2014:561459. doi: 10.1155/2014/561459. Epub 2014 Apr 30. PMID: 24876674; PMCID: PMC4021678 Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014 Jun 5;510(7503):92-101. doi: 10.1038/nature13479. PMID: 24899309; PMCID: PMC4263681
  11. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014 Jun 5;510(7503):92-101. doi: 10.1038/nature13479. PMID: 24899309; PMCID: PMC4263681
  12. Di Nicola V. Degenerative osteoarthritis a reversible chronic disease. Regen Ther. 2020 Aug 15;15:149-160. doi: 10.1016/j. reth.2020.07.007. PMID: 33426213; PMCID: PMC7770340
  13. Strümper R. Intraarticular Injections of Autologous Conditioned Serum to Treat Pain from Meniscal Lesions. SportMedInt open. 2017 Oct 29;1(6):E200–E205. PMID: 30539108
  14. Jones IA, Togashi RC, Thomas Vangsness C Jr. The Economics and Regulation of PRP in the Evolving Field of Orthopedic Biologics. Curr Rev Musculoskelet Med. 2018 Dec;11(4):558-565. doi: 10.1007/s12178-018-9514-z. PMID: 30116992; PMCID: PMC6220002
  15. Harrold AJ. The defect of blood coagulation in joints. J Clin Pathol. 1961 May;14(3):305-8. doi: 10.1136/jcp.14.3.305. PMID: 13711857; PMCID: PMC480217.
  16. Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to acti-vation and propagation of the complement system. J Exp Med. 2005 Mar 21;201(6):871-9. doi: 10.1084/jem.20041497. PMID: 15781579; PMCID: PMC2213112
  17. van Meegeren ME, Roosendaal G, Barten-van Rijbroek AD, Schutgens RE, Lafeber FP, Mast-bergen SC. Coagulation aggravates blood-induced joint damage in dogs. Arthritis Rheum. 2012 Oct;64(10):3231-9. doi: 10.1002/art.34552. PMID: 22674062References
  1. Drakos M et al: Injury in the National Basketball Association, A 17-Year Overview. Sports Health. 2010 Jul; 2(4): 284–290. doi: 10.1177/1941738109357303

References for Table „Spectrum of Treatment Options (2)“

  1. Baltzer AW, Moser C, Jansen SA, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage. 2009 Feb;17(2):152-60. doi: 10.1016/j.joca.2008.06.014. Epub 2008 Jul 31. PMID: 18674932.
  2. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, Blanco FJ, Espinosa R, Haugen IK, Lin J, Mandl LA, Moilanen E, Nakamura N, Snyder-Mackler L, Trojian T, Underwood M, McAlindon TE. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. Elsevier Ltd; 2019;27(11):1578–1589. PMID: 31278997. Supplementary Material „Evidence Report: OARSI Treatment Guidelines for the Non-Surgical Management of Osteoarthritis“ 09/2018.
  3. Filardo G, Di Matteo B, Di Martino A, Merli ML, Cenacchi A, Fornasari P, Marcacci M, Kon E. Platelet-Rich Plasma Intra- articular Knee Injections Show No Superiority Versus Viscosupplementation: A Randomized Controlled Trial. Am J Sports Med. 2015 Jul 7;43(7):1575–82. PMID: 25952818
  4. Cole BJ, Karas V, Hussey K, Pilz K, Fortier LA. Hyaluronic Acid Versus Platelet-Rich Plasma: A Prospective, Double-Blind Randomized Controlled Trial Comparing Clinical Outcomes and Effects on Intra-articular Biology for the Treatment of Knee Osteoarthritis. Am J Sports Med. 2017 Feb 21;45(2):339–346. PMID: 28146403. 3 injections
  5. Joshi Jubert N, Rodríguez L, Reverté-Vinaixa MM, Navarro A. Platelet-Rich Plasma Injections for Advanced Knee Osteoarthritis: A Prospective, Randomized, Double-Blinded Clinical Trial [vs GC]. Orthop J Sport Med. 2017 Feb 13;5(2):232596711668938. PMID: 5315239
  6. Lu L, Dai C, Zhang Z, Du H, Li S, Ye P, Fu Q, Zhang L, Wu X, Dong Y, Song Y, Zhao D, Pang Y, Bao C. Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells [vs HA]: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial. Stem Cell Res Ther. Stem Cell Research & Therapy; 2019;10(1):143. PMID: 31113476
  7. Bastos R, Mathias M, Andrade R, Amaral RJFC, Schott V, Balduino A, Bastos R, Miguel Oliveira J, Reis RL, Rodeo S, Espregueira-Mendes J. Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma [vs GC] is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial. Knee Surg Sports Traumatol Arthrosc. Springer Berlin Heidelberg; 2019 Oct 5;(0123456789). PMID: 31587091

Effect size calculation: (Sawilowsky SS. New Effect Size Rules of Thumb. doi:10.22237/jmasm/1257035100): Effect Size (ES), Cohen’s d, SMD) = very small (<0.01), small (0.2), medium (0.5), large (0.8), very large (1.2), huge (2.0)

NNT calculation: calculated on the basis of ES pain via https://rpsychologist.com/d3/cohend/

The content of this website is intended solely for general information about the Regenokine Program.  The general information is compiled to the best of current knowledge (January 2021). At the same time, that knowledge about the Regenokine Program is always evolving. This information is in no way a substitute for a personal consultation with a Doctor. It is intended to help you prepare for an appointment with a licensed Doctor of the Regenokine Program. Although the greatest possible care has been taken in the preparation of this content, there cannot guarantees that the information it contains is free of errors and accurate.

The contents of this website are subject to German (and American) copyright law. Duplication, processing, distribution, or any form of commercialization of such material beyond the scope of the copyright law shall require the prior written consent of Prof. Dr. Peter Wehling, as the copyright owner. Copies of the content are only permitted for private use, but not for commercial use. Insofar as the content of the website was not created by the medical practice, the copyrights of third parties are respected. In particular, third-party content is identified as such. Should you nevertheless become aware of a copyright infringement, please inform us accordingly. If we become aware of any infringements, we will remove such content immediately.

Press & Testimonials

Kobe Bryant's $3 million possible deal to play 10 games in Italy during the NBA lockout was aided by a former physician to Pope John Paul II who treated the Lakers star this summer with a pioneering blood treatment.

Bryant traveled to Dusseldorf, Germany, in June for treatment, as previously reported. ESPN The Magazine has learned that he was treated by Dr. Peter Wehling, an influential but little-known molecular orthopedist who insists he's having breakthrough success repairing joints by manipulating his patients' blood. [Read More...]
Kobe Bryant is returning to Germany for another innovative knee procedure, according to people with knowledge of the situation.
Recovery from Orthokine or Regenokine is typically quick compared to more severe knee procedures and does not add to Bryant's recovery time from a torn Achilles' tendon, which remains the larger issue. His availability for the Lakers' Oct. 29 season opener against the Clippers is till unclear.
[Read More...]
[...] "Alex was interested in pursuing it as long as the Yankees' medical staff was comfortable with it and vetted the process. He basically asked up to look into it.

"I think he's 100 percent right now, personally," Cashman added. "Hopefully going forward he'll be healthy for us again, because when he is healthy he's obviously one of the best players in the game."

Rodriguez, who had arthroscopic surgery on his troublesome right knee in July, underwent the experimental procedure with Dr. Peter Wehling during a December 5-9 trip to Dusseldorf. [Read More...]
Düsseldorf, Germany
The medical treatment for Lindsey Berg's arthritic left knee has not been approved by the Food and Drug Administration, and neither her professional volleyball team in Italy nor the United States Olympic team would help with the cost. But for Berg, a gold medal hopeful, the chance to dull the chronic pain was worth the money, and the risk. [Read more...]
Tracy McGrady was one of the best basketball players in the world, a seven-time All-Start forward and a scoring machine, until he suffered a devastating knee injury in 2008.

When McGrady returned to the game after two operations on his left knee, he was a shadow of the player he had been before.

"It was tough to deal with because at one minute, you're playing so well, you know, on top of your game, the next minute, you're not even valuable no more," he said. "Where do I go from here?" [Read More...]
In 2011, after sitting out much of the season due to chronic pain in his right knee, Los Angeles Lakers star Kobe Bryant – who already had undergone three knee surgeries – decided to try something different to get his game back: He traveled to Düsseldorf, Germany. That’s where a physician named Peter Wehling invented an innovative procedure called Regenokine, which uses the body’s own anti-inflammatory proteins and human-growth factors to reverse pain and chronic injuries. By all accounts, Bryant’s visit was a success – he went from a possibly career-ending injury to being back on the court. “I can run. I can jump. I can run the track. I can practice every day. Those are things I couldn’t do last year,” he told Yahoo! Sports at the time. [Read More...]

Donna K., NYC

 Age: 67 

“Miraculously, within weeks of the Regenokine treatment my pain had diminished from a constant 7/10 with medications to 4/10 without!“ [Read more…]

Area Treated: Back

Svetlana S., Boston

 Age: 61 

“At the last day of my treatment, pain in my neck disappeared (stage 4 – untreatable), shoulder become 70% better low back/arthritis and prolapsed disk – very, very big difference“ [Read more…]

Area Treated: Oseteoarthritis

Ulla M.-C., California

 Age: 76 

“The Regenokine treatment for my severe osteoarthritis in both my hands has, proved to be very beneficial. I now have a lot more flexibility in my hands. Everyday chores are much easier to perform.“ [Read more…]

Area Treated: Hands

Donna G., Washington D.C.

 Age: 63 

“With Regenokine, I was able to ski again, after two years not being able to ski due to pain.“ [Read more…]

Area Treated: Back

Peter L., Hungary

 Age: 34 

“After the Regenokine treatment, I got back the strengths of my knee, I did not have pain every day.“ [Read more…]

Area Treated: Knee

Daniel S. Germany

 Age: 37 

“After the second injection I was feeling much better and after the 3rd injection I felt an improvement of 40 percent. The pain was gone and my quality of life improved a lot. An operation was not necessary anymore.” [Read more…]

Area Treated: Back

View the Brochure

Read the book The End of Pain – As sold on Amazon!

Written by Dr. Peter Wehling & Dr. Christian Renna

end of pain book

Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.